Craniectomy Decompression : Relieving Pressure on the Brain | My Medic Plus — Cost, Top Hospitals & Success Rates | MyMedicPlus

Decompressive craniectomy is a life-saving neurosurgical procedure in which a portion of the skull — typically 10–15 cm in diameter — is temporarily removed to allow a swollen brain to expand without being compressed against the rigid skull vault. When intracranial pressure (ICP) rises above 20–25 mmHg due to oedema, haematoma, or infarction, cerebral perfusion is critically compromised. By removing the bone flap, surgeons create space that reduces ICP, restores blood flow to threatened brain tissue, and prevents herniation of the brainstem — a rapidly fatal event.

The operation is performed under general anaesthesia. The neurosurgeon creates a large scalp incision, drills a series of burr holes, and cuts between them with a craniotome to free the bone flap. The dura mater (the brain's outer membrane) is opened in a stellate or curvilinear pattern and a dural patch graft — typically from synthetic material or autologous pericranium — is sutured in to further enlarge the compartment. The bone flap is stored either in a subcutaneous abdominal pocket or in a sterile bone bank at -80 °C for later reimplantation.

Following stabilisation — usually three to twelve months later — cranioplasty is performed to replace the bone flap or to insert a custom-made titanium or PEEK implant, restoring skull integrity and protecting the brain. The timing of cranioplasty significantly influences cognitive and neurological outcomes: studies published in the Journal of Neurosurgery show that early cranioplasty (within 90 days) may accelerate neurological recovery compared with late replacement.

Decompressive craniectomy is one of the most technically demanding emergency neurosurgical procedures. Its success depends on rapid patient assessment, experienced neurosurgical teams, and well-equipped neurointensive care units. Leading centres in India, Thailand, and Turkey offer this procedure at a fraction of Western costs while maintaining JCI-accredited standards of care.

Decompressive craniectomy is indicated primarily for conditions that cause catastrophic rises in intracranial pressure unresponsive to maximal medical therapy. The most common indication is severe traumatic brain injury (TBI) with diffuse cerebral swelling or large contusions — a scenario encountered in road traffic accidents, falls, and assault. In randomised trials such as DECRA and RESCUEicp, craniectomy consistently reduced ICP and lowered mortality compared with continued medical management alone.

The procedure is also performed for malignant middle cerebral artery (MCA) ischaemic stroke, in which massive hemispheric infarction causes fatal herniation in up to 80% of patients without surgical intervention. The DESTINY II trial demonstrated that craniectomy in patients over 60 years old with malignant MCA stroke significantly reduced mortality, although with some survivors experiencing moderate-to-severe disability. Additional indications include spontaneous intracerebral haematoma causing intractable ICP elevation, cerebral venous sinus thrombosis with refractory oedema, fulminant meningitis or encephalitis with severe cerebral swelling, and post-operative oedema following other cranial procedures.

Ideal candidates for decompressive craniectomy are patients with documented intracranial hypertension (ICP >25 mmHg for more than 30 minutes despite optimised first-line medical management) or clinical evidence of imminent herniation — ipsilateral pupillary dilation, bilateral extensor posturing, or rapid neurological deterioration. In the setting of malignant MCA infarction, surgery is most beneficial when performed within 48 hours of symptom onset in patients under 60 years of age, although benefit extends to carefully selected older patients. Pre-operative imaging (CT or MRI) must confirm significant mass effect with midline shift greater than 5 mm.

Contraindications include bilateral fixed dilated pupils persisting for more than six hours (indicating irreversible brainstem injury), severe pre-existing neurological disability that precludes meaningful recovery, or advanced systemic illness incompatible with survival of the peri-operative period. Patients with advanced coagulopathy must be stabilised before surgery. The decision must incorporate family discussions about realistic neurological outcomes, as a proportion of survivors — particularly elderly patients — will have significant disability requiring long-term care.

The two principal craniectomy configurations are unilateral (hemicraniectomy) and bilateral (bifrontal) decompression. Hemicraniectomy is the standard approach for unilateral lesions such as malignant MCA stroke or unilateral contusion, with the bone flap removed over the affected hemisphere extending at least 12 cm in diameter — smaller craniectomies are associated with paradoxical worsening from 'slit syndrome'. Bifrontal craniectomy, in which bone is removed across both frontal lobes, is preferred for diffuse TBI with bilateral frontal contusions, and includes opening the interhemispheric dura to allow mid-frontal expansion.

Adjunct intraoperative techniques include durotomy with duraplasty — mandatory for achieving adequate decompression — and evacuation of haematoma or contused tissue when present. Intraoperative ICP monitoring guides the adequacy of decompression. Postoperatively, patients are managed in a neurointensive care unit with continuous ICP monitoring via an intraparenchymal probe, ventilatory control of PaCO2, osmotherapy with hypertonic saline or mannitol, maintained cerebral perfusion pressure (CPP >60 mmHg), and targeted temperature management. The RESCUE-ASDH trial (2023) is evaluating optimal timing of craniectomy versus craniotomy specifically in acute subdural haematoma. The treating surgeon individualises the chosen technique based on patient anatomy, the extent and nature of the underlying condition, available equipment, and the balance of procedural benefit against risk — a decision made in consultation with the patient following a thorough informed consent discussion covering all available options.

The primary benefit of decompressive craniectomy is prevention of death from brain herniation. The RESCUEicp randomised trial (Cooper et al., NEJM 2016) demonstrated that craniectomy reduced mortality at six months from 48.9% to 26.9% compared with medical management alone in severe TBI with refractory ICP. Among malignant MCA stroke patients, HAMLET, DESTINY, and DECIMAL trials showed that hemicraniectomy reduced mortality from approximately 70% to 25%, albeit with a proportion of survivors experiencing moderate disability (modified Rankin Scale 3–4).

Long-term neurological recovery continues for 12–24 months post-injury. Factors associated with better outcomes include younger age, higher GCS score at presentation, earlier surgical intervention, absence of bilateral brainstem involvement, and prompt cranioplasty. Many patients regain meaningful functional independence — studies report that 30–40% of TBI patients and 50–60% of malignant MCA stroke survivors achieve functional independence (mRS 0–3) at one year. Early and intensive neurorehabilitation — incorporating physiotherapy, occupational therapy, speech therapy, and cognitive rehabilitation — is essential to maximise recovery.

Decompressive craniectomy carries significant perioperative risks inherent to major neurosurgical intervention on critically ill patients. Intraoperative risks include massive haemorrhage, arterial or venous sinus injury during bone removal, and iatrogenic brain injury. The reported 30-day surgical mortality is 5–15% in elective series but higher in emergency trauma settings. Early postoperative complications include wound dehiscence and infection (3–8%), contralateral haematoma formation due to pressure redistribution, cerebral oedema worsening despite decompression, seizures requiring anticonvulsant therapy, and cerebrospinal fluid (CSF) leak or hygroma formation (10–20% of cases).

Delayed complications include sinking skin flap syndrome (syndrome of the trephined) — a paradoxical neurological deterioration when the skin flap sinks inward under atmospheric pressure, causing altered consciousness and motor deficits reversible with cranioplasty. Bone flap resorption occurs in 15–25% of autologous reimplantations, necessitating custom implant fabrication. Deep vein thrombosis and pulmonary embolism are significant risks during prolonged immobility in the ICU. Long-term complications include post-traumatic epilepsy (20–30%), hydrocephalus requiring ventriculoperitoneal shunting (5–10%), chronic subdural hygroma, cognitive impairment, and neuropsychiatric sequelae including depression, anxiety, and personality changes.

The immediate post-operative period is managed in a neurological ICU where ICP, CPP, EEG, and multi-modal neuromonitoring guide therapy. Patients are gradually weaned from sedation and ventilatory support as ICP stabilises — typically over 7–14 days. Rehabilitation begins in the ICU with passive limb movements and is progressively intensified as consciousness and medical stability improve. Transfer to a dedicated neurorehabilitation unit occurs once the patient is haemodynamically stable, usually within 2–4 weeks.

Cranioplasty — replacement of the bone flap or custom implant — is scheduled 3–6 months after craniectomy once cerebral swelling has resolved and the patient is sufficiently rehabilitated to tolerate a second anaesthetic. MRI or CT perfusion scanning before cranioplasty helps identify patients most likely to benefit from early replacement. After cranioplasty, rehabilitation continues for 6–24 months. Long-term follow-up includes neurology clinic reviews every 3–6 months for seizure management, neuropsychological testing, neurorehabilitation goal-setting, and monitoring for hydrocephalus with serial imaging. Patients are advised to wear a protective helmet when the craniectomy site is uncovered and to avoid contact sports and high-fall activities indefinitely.

In the United States, decompressive craniectomy with ICU care and subsequent cranioplasty can cost USD 80,000–200,000 depending on length of stay, implant type, and complications. UK NHS provision is free at the point of care for eligible patients, but private neurosurgical care is similarly expensive. These costs place the combined treatment beyond the reach of uninsured patients internationally.

Leading medical tourism destinations offer this procedure at dramatically lower cost without compromising quality. In India (Apollo, Fortis, Manipal), the combined cost of emergency craniectomy, ICU stay, cranioplasty, and early rehabilitation ranges from USD 8,000–20,000 — representing savings of 75–85%. Thailand (Bumrungrad, Samitivej) and Turkey (Acibadem, Memorial) charge USD 12,000–25,000 for comparable care. All these centres feature neurosurgeons trained at leading Western institutions, JCI accreditation, dedicated neurointensive care units, and ICP monitoring infrastructure meeting international guidelines.

Medical management of intracranial hypertension — the alternative to surgical decompression — includes sedation, analgesia, head-of-bed elevation, hyperosmolar therapy with mannitol or hypertonic saline, controlled hyperventilation, and barbiturate coma. These measures reduce ICP by 5–15 mmHg and are the first-line approach. However, when ICP remains above 25 mmHg despite optimised medical therapy, evidence supports surgical decompression as the superior strategy for reducing mortality and improving outcomes.

For selected TBI patients with a focal haematoma rather than diffuse swelling, standard craniotomy with haematoma evacuation and watertight dural closure may be sufficient without the wider bone removal of craniectomy. Endoscopic or minimally invasive haematoma evacuation is an emerging alternative for deep-seated haematomas in specialised centres. Lumbar CSF drainage can reduce ICP temporarily in refractory cases without mass lesion. Hypothermia protocols (32–35°C) have been trialled as ICP-lowering alternatives but have not demonstrated survival benefit in large randomised trials, limiting their clinical use outside research settings.